Rick Doblin

Founder and President of MAPS

Data updated

Papers

28 publications

Trials

0 clinical trials

Research Footprint

Rick Doblin appears in 28 tracked papers (1991–2024), most studied alongside MDMA, Placebo and Psilocybin, across PTSD, Safety & Risk Management and Anxiety Disorders.

Most-cited paper: MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study (942 citations).

Frequent co-authors: Berra Yazar-Klosinski, Michael Mithoefer and Amy Emerson.

Background & Research

Rick Doblin is the founder of the Multidisciplinary Association for Psychedelic Studies (MAPS). For over three decades, he has led efforts to establish psychedelics as prescription medicines, focusing on the FDA approval of MDMA for PTSD. His work bridges public policy, clinical science, and advocacy, aiming to create a legal and safe context for the beneficial use of psychedelics for healing and growth.

Key Impact

The central figure in the global advocacy and regulatory maturation of MDMA-assisted therapy.

28

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

39 collaborators· click a node to visit their profile

Full network →

Compounds

MDMAPlaceboPsilocybinLSDAyahuasca

Topics

PTSDSafety & Risk ManagementAnxiety DisordersDepressive DisordersSubstance Use Disorders (SUD)Interpersonal Functioning & Social ConnectednessSuicidalitySet & SettingAdolescentsVeteransPersonality & Trait FactorsPalliative & End-of-Life DistressNeurocognitive DisordersNeuroimaging & Brain MeasuresAutism Spectrum Disorder (ASD)CreativityEquity and EthicsPublic Health, Prevention & Behaviour ChangeEating DisordersMajor Depressive Disorder (MDD)Treatment-Resistant Depression (TRD)Health Economics & ReimbursementAlcohol Use Disorder (AUD)

Top Collaborators

Affiliations

Institutions, companies, and organisations Rick Doblin is associated with.

MAPS

nonprofit

MAPS, the Multidisciplinary Association for Psychedelic Studies, is a U.S.-based 501(c)(3) nonprofit research and educational organization founded in 1986. It works nationally and with a broader global audience to develop medical, legal, and cultural contexts for the careful use of psychedelics and marijuana. Its core activities include research, education, advocacy, and convening the field through large public events. In psychedelic medicine and policy, MAPS positions itself as an advocate for legal access, drug policy reform, harm reduction, and health equity. Its Policy & Advocacy work includes legislative advocacy, community organizing, and impact litigation, and it has also launched work on access for system-impacted people and broader health equity in the legal psychedelic ecosystem. Current documented initiatives include the Psychedelic Science conference series, the Health Equity Program, The Zendo Project, and Ask MAPS, which handles public inquiries about therapy, research, and policy reform.

View stakeholder →